Management of Cancer-Associated Myositis
Tóm tắt
Cancer-associated myositis (CAM) is defined as when cancer appears within 3 years of myositis onset. Dermatomyositis and seronegative immune–mediated necrotizing myopathy are the phenotypes mostly related to cancer. In general, treatment principles in myositis patients with and without CAM are similar. However, some aspects of myositis management are particular to CAM, including (a) the need for a multidisciplinary approach and a close relationship with the oncologist, (b) the presence of immunosuppressive and antineoplastic drug interactions, and (c) the role of the long-term immunosuppressive therapy as a risk factor for cancer relapse or development of a second neoplasm. In this review, we will also discuss immunotherapy in patients treated with checkpoint inhibitors as a treatment for their cancer. Studies on cancer risk in patients treated with long-term immunosuppressive drugs, in autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis, and in solid organ transplant recipients have shed some light on this topic. Immunotherapy, which has been a great advance for the treatment of some types of malignancy, may be also of interest in CAM, given the special relationship between both disorders. Management of CAM is a challenge. In this complex scenario, therapeutic decisions must consider both diseases simultaneously.
Tài liệu tham khảo
Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84:231–49.
Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326:363–7.
Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100.
Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134:1087–95.
Selva-O’Callaghan A, Trallero-Araguás E. Myositis and cancer. In: Graus F, Editor-in-Chief. MedLink Neurology. San Diego: MedLink LLC. Available at www.medlink.com. Updated: [8.31.2021].
Selva-O’Callaghan A, Pinal-Fernández I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17:816–28. A comprehensive review on the classification and management of inflammatory myopathies that include the most accepted clinic-immunological phenotypes.
Oldroyd AGS, Allard AB, Callen JP, et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021;60:2615–28. In this systematic review and meta-analysis of 69 studies, main cancer risk factors in patients with idiopathic inflammatory myopathies are described.
Alexanderson H, Boström C. Exercise therapy in patients with idiopathic inflammatory myopathies and systemic lupus erythematosus — a systematic literature review. Best Pract Res Clin Rheumatol. 2020;34:101547. An excellent review focused on the physical therapy and its benefits in patients with myositis.
Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003;48:2285–93.
Love LA, Weinberg CR, McConnaughey DR, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009;60:2499–504.
Shinjo SK, de Souza FHC, Borges IBP, et al. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology (Oxford). 2021;19:keab773. https://doi.org/10.1093/rheumatology/keab773. This prospective controlled study demonstrates that Sinovac-Coronavac is safe for patients with myositis although the presence of neutralizing antibodies was reduced in comparison with a control group.
Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R. Risk factors and cancer screening in myositis. Rheum Dis Clin North Am. 2020;46:565–76.
Kaneko Y, Ninawa T, Taniguchi Y, et al. JAMI investigators. Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study. Rheumatology (Oxford). 2020;59:112–9.
András C, Bodoki L, Nagy-Vincze M, Griger Z, Csiki E, Dankó K. Retrospective analysis of cancer-associated myositis patients over the past 3 decades in a Hungarian myositis cohort. Pathol Oncol Res. 2020;26:1749–55.
Saraswat N, Verma R, Neema S, Kumar S. A case of capecitabine-induced dermatomyositis. Indian J Pharmacol. 2018;50:350–3.
Chen FW, Zhou X, Egbert BM, Swetter SM, Sarin KY. Dermatomyositis associated with capecitabine in the setting of malignancy. J Am Acad Dermatol. 2014;70:e47–8.
Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003;48:439–41.
European Medicines Agency (EMA). Medicinal products for human use. Summary of Product Characteristics, 2022. Available at: https://www.ema.europa.eu/en/human-medicines-regulatory-information. Last access: 25th January 2022.
Food and Drug Administration (FDA). Drugs. Summary of Product Characteristics and Safety Information, 2022. Available at: https://www.fda.gov/Drugs. Last access: 25th January 2022.
Wishart DS, Knox C, Guo AC, et al. Drug bank: a knowledge base for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36(Database issue):D901-6.
Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol. 2017;52:20–33.
Selva-O’Callaghan A, Palacios A, Solans-Laque R, Labirua A, Salcedo-Allende T, Vilardell-Tarrés M. Epstein-Barr virus-associated lymphoma in patients with dermatomyositis. Be aware of double immunosuppression. Rheumatology (Oxford). 2009;48:1462–3.
Singh N, Li CI. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence. Curr Opin Rheumatol. 2021;33:292–9.
Cangemi M, Montico B, Faè DA, Steffan A, Dolcetti R. Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients. Front Oncol. 2019;9:160.
Ytterberg SR, Bhatt DL, Mikuls TR, et al. ORAL Surveillance investigators Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–26. A higher risk of cancer was detected in patients with rheumatoid arthritis treated with tofacitinib in comparison with those treated with TNF inhibitors after a period of 4 years follow-up.
Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381:291–3.
Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73:858–65.
Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670–7.
Wadstrom H, Frisell T, Askling J, Anti-rheumatic therapy in Sweden study G. malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 2017;177:1605–12.
Emery P, Furst DE, Kirchner P, et al. Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data. Rheumatol Ther. 2020;7:121–31.
Shin JI, Li H, Park S, et al. Induction and maintenance treatment of Lupus nephritis: a comprehensive review of meta-analyses. J Clin Med. 2022;11:343.
Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. Semin Arthritis Rheum. 2020;50:930–7.
Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013;119:2300–8.
Haller MC, Royuela A, Nagler EV, Pascual J, Webster AC. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev. 2016;22:CD005632.
Cho HG, Kuo KY, Xiao K, et al. Azathioprine and risk of multiple keratinocyte cancers. J Am Acad Dermatol. 2018;78:27–8.
Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transplant. 2016;16:3490–503.
Hirunsatitpron P, Hanprasertpong N, Noppakun K, Pruksakorn D, Teekachunhatean S, Koonrungsesomboon N. Mycophenolic acid and cancer risk in solid organ transplant recipients: systematic review and meta-analysis. Br J Clin Pharmacol. 2021;8. https://doi.org/10.1111/bcp.14979. Data retrieved from this systematic review and meta-analysis help to establish the true risk of cancer in patients receiving therapy with mycophenolate mofetil. This therapy was not associated with an increased risk of cancer.
Le Saux O, Lounici Y, Wajda P, et al. Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. Crit Rev Oncol Hematol. 2021;157:103172.
Florou V, Puri S, Garrido-Laguna I, Wilky BA. Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Ann Transl Med. 2021;9:1035.
Abdel-Wahab N, Shah M, López-Olivo MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med. 2018;169:133.
Tison A, Quéré G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71:2100–11.
Kaur A, Doberstein T, Amberker RR, et al. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Medicine (Baltimore). 2019;98:e17348.
Takatsuki K, Yanagihara T, Egashira A, et al. A rare case of pembrolizumab-induced dermatomyositis in a patient with cancer of unknown primary origin. Am J Case Rep. 2021;22:e930286.
Thomas R, Patel H, Scott J. Dermatomyositis flare with immune checkpoint inhibitor therapy for melanoma. Cureus. 2021;13:e14387.
Messer A, Drozd B, Glitza IC, Lu H, Patel AB. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. Dermatol Online J. 2020;26:13030/qt4c21b068.
Kosche C, Stout M, Sosman J, Lukas RV, Choi JN. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature. Melanoma Res. 2020;30:313–6.
Shibata C, Kato J, Toda N, et al. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report. J Med Case Rep. 2019;13:168.
Selva-O’Callaghan A, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM. Differential diagnosis of necrotizing myopathy. Curr Opin Rheumatol. 2021;33:544–53.
Matas-García A, Milisenda JC, Selva-O'Callaghan A, et al. Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev. 2020; 19:102455. A characteristic clinical and pathological picture was depicted in the analysis of patients with checkpoint inhibitors associated myopathy.